1-3 of 3
Catherine Bagot
Close
Sort by
Journal Articles

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

CME Clinical Trials & Observations
Andrew J. Doyle, Matthew J. Stubbs, Tina Dutt, Will Lester, Will Thomas, Joost van Veen, Joannes Hermans, Tanya Cranfield, Quentin A. Hill, Amanda Clark, Catherine Bagot, Steven Austin, John-Paul Westwood, Mari Thomas, Marie Scully
Journal: Blood
Blood (2023) 141 (3): 285–294.
https://doi.org/10.1182/blood.2022017023
Published: 2023
Journal Articles

A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial

Charlotte A Bradbury, MD MSc, FRCP, FRCPath, PhD, Rosemary Greenwood, Julie Pell, Katie Breheny, Rebecca Kandiyali, Jenny Ingram, Ian Thomas, Catherine Bagot, MD FRCPath, MBBS, Quentin Hill, HaemSTAR Collaborators, Nichola Cooper
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-2.
https://doi.org/10.1182/blood-2020-143563
Published: 2020
Journal Articles

Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study

Nichola Cooper, MRCP, Andrew Provan, Marie Scully, MD MRCP, FRCPath, Henri Grech, Catherine Bagot, MD FRCPath, MBBS, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Tim Nokes, Nicholas Ramscar, Luke Saunders
Journal: Blood
Blood (2018) 132 (Supplement 1): 2426.
https://doi.org/10.1182/blood-2018-99-110126
Published: 2018